Key points from article :
Swiss longevity company Timeline has successfully completed a clinical study (MitoImmune) demonstrating that their proprietary ingredient, Mitopure, can rejuvenate aging immune systems by boosting T-cell function.
This study, conducted with the Georg-Speyer-Haus Institute and the Buck Institute of Aging, showed increased levels of youthful T-cells and improved mitochondrial activity in participants who took Mitopure.
Building on these findings, Timeline is launching two new clinical trials with the National Institute of Aging and National Institute of Cancer to explore Mitopure's potential in improving metabolic health and reducing oxidative stress in cancer patients.
Timeline's mission is to develop clinically proven interventions that support healthy aging, and their work is backed by over a decade of research and multiple patents.
Mitopure, derived from Urolithin A, is a key part of Timeline's approach to improving cellular health and extending a healthy lifespan.
Investors in Timeline include Nestlé Health Science and L’Oréal.
